Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05297909 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Ascending doses in healthy volunteers |
| Part 2: CSF PKPD | EXPERIMENTAL | Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment |
| Name | Type | Description |
|---|---|---|
| PF-05297909 25 mg | DRUG | Single oral (PO) dose, PF-05297909 25 mg |
| PF-05297909 100 mg | DRUG | Single oral (PO) dose, PF-05297909 100 mg |
| PF-05297909 250 mg | DRUG | Single oral (PO) dose, PF-05297909 250 mg |
| PF-05297909 525 mg | DRUG | Single oral (PO) dose, PF-05297909 525 mg |
Inclusion Criteria: * For Healthy adult volunteers: healthy male and/or female subjects of non child bearing potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, inc...
PF-05297909 is an investigational small molecule being studied in healthy adults. It is being evaluated for safety and to measure its concentrations in blood and cerebrospinal fluid after a single dose. It is not approved for any condition and remains in clinical development.
PF-05297909 is being developed by Pfizer, Inc., which trades under the ticker PFE. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
PF-05297909 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The single Phase 1 trial has been completed.
PF-05297909 has one completed Phase 1 trial, NCT01462851. This study evaluated the safety and concentrations of PF-05297909 in blood and cerebrospinal fluid after a single dose in 51 healthy adults in the United States.
PF-05297909 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy volunteers. It remains in clinical development and has not been authorized for any medical use.